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Red Cell Biology & Its Disorders
Introduction
HbSC disease is the second commonest form of sickle cell
disease in African populations, but both its pathophysiologi-
cal and clinical aspects are poorly understood. It affects about
2% of the population in West Africa, with recorded inci-
dences of up to 25% in some areas, such as Burkina Faso and
Northern Ghana.1 It is less severe than sickle cell anemia
(HbSS), with half the prevalence of acute pain,2 and life
expectancy up to 20 years longer.3 However, serious compli-
cations occur: people with HbSC disease have a 100 times
higher risk of stroke compared to the general population,4 and
an increased risk of proliferative retinopathy, with up to 70%
of adults affected.5 As with all types of sickle cell disease,
there is marked, unexplained clinical variability: about 50%
patients report no episodes of pain per year, whereas a minor-
ity suffer severe pain more than six times per year.2 Equally,
steady-state hemoglobin levels vary widely, from 7 g/dL to 14
g/dL.6 Clinical management is inferred from studies of HbSS,
with little evidence that this is appropriate, and there are no
specific treatments for HbSC disease.
The pathophysiology of HbSC disease is very different
from that of HbSS. For example, blood concentrations of
hemoglobin and creatinine are significantly higher in HbSC
than in HbSS, whereas concentrations of white cells, reticulo-
cytes, lactate dehydrogenase and HbF are significantly lower.7
HbS polymerization, red cell dehydration and vaso-occlusion
are central to the pathology of both HbSC and HbSS.8
However, the concentration of HbS in red cells from patients
with HbSC is only 40-50%, significantly less than the 80-95%
in HbSS. The rate of HbS polymerization is critically depend-
ent on the intra-erythrocytic concentration of HbS, and so it
is surprising that HbSC patients develop vaso-occlusion,
given that sickle cell carriers (HbAS), with HbS levels of 30-
40%, are largely asymptomatic.9
The explanation for the vaso-occlusive nature of HbSC ery-
throcytes is believed to center on the fact they leak cations
and water, thereby increasing the concentration of HbS to
critical levels. Oxygenated HbSC erythrocytes show an exag-
gerated potassium efflux in response to volume increase, and
this is dependent on chloride ions, and stimulated by N-eth-
ylmaleimide, which is characteristic of K-Cl cotransport
(KCC).10 There is evidence that this dehydration is due to an
interaction between the HbC and KCC molecules present in
the red cell membrane, although the exact mechanism is
unknown.9 HbC is known to bind to the cytoplasmic region
of band 3,11 although it is unclear how this leads to erythro-
cyte dehydration.12
KCC activation has been established to be central to the
pathophysiology of HbSC disease, with many experiments
demonstrating its importance in vitro.13 In this study we inves-
tigated the hypothesis that variation in KCC activity is
responsible for some of the phenotypic variation seen in
HbSC disease, including differences in hospital attendance,
retinopathy and the degree of anemia. We also assessed how
KCC activity varies with age, sex and other parameters to try
and understand how this variation occurs.
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HbSC disease is the second commonest form of sickle cell disease, with poorly understood pathophysiology and
few treatments. We studied the role of K-Cl cotransport activity in determining clinical and laboratory features,
and investigated its potential role as a biomarker. Samples were collected from 110 patients with HbSC disease
and 41 with sickle cell anemia (HbSS). K-Cl cotransport activity was measured in the oxygenated (K-Cl cotrans-
port100) and deoxygenated (K-Cl cotransport0) states, using radioactive tracer studies. K-Cl cotransport activity was
high in HbSC and decreased significantly on deoxygenation. K-Cl cotransport activity correlated significantly and
positively with the formation of sickle cells. On multiple regression analysis, K-Cl cotransport increased signifi-
cantly and independently with increasing reticulocyte count and age. K-Cl cotransport activity was increased in
patients who attended hospital with acute pain in 2011 compared to those who did not (K-Cl cotransport100: mean
3.87 versus 3.20, P=0.009, independent samples T-test; K-Cl cotransport0: mean 0.96 versus 0.68, P=0.037). On logis-
tic regression only K-Cl cotransport was associated with hospital attendance. Increased K-Cl cotransport activity
was associated with the presence of retinopathy, but this effect was confounded by age. This study links variabil-
ity in a fundamental aspect of cellular pathology with a clinical outcome, suggesting that K-Cl cotransport is central
to the pathology of HbSC disease. Increased K-Cl cotransport activity is associated with increasing age, which
may be of pathophysiological significance. Effective inhibition of K-Cl cotransport activity is likely to be of ther-
apeutic benefit.
The clinical significance of K-Cl cotransport activity in red cells
of patients with HbSC disease
David C. Rees1, Swee Lay Thein,2 Anna Osei,1 Emma Drasar,2 Sanjay Tewari,1 Anke Hannemann,3 and John S Gibson3
1Department of Paediatric Haematology, King’s College Hospital, King’s College London School of Medicine; 2Department of
Haematological Medicine, King’s College Hospital, King’s College London School of Medicine; and 3Department of Veterinary




The study was approved by the National Research Ethics
Committee London-East (reference 11/LO/0065). All partici-
pants gave written informed consent and the research was con-
ducted in accordance with the Helsinki Declaration of 1975, as
revised in 2008. 
Patients were recruited from adults and children (>2 years old)
attending clinics at King’s College Hospital in south London, UK.
Approximately 300 patients with HbSC and 700 with HbSS are
followed at our hospital. Patients with HbSC and HbSS were
recruited sequentially as they attended clinic appointments, the
latter for comparison to identify the specific significance of KCC
in HbSC disease. All diagnoses of sickle cell disease were con-
firmed by family, hematologic and DNA studies, as appropriate.
All patients were in the steady-state, with no acute symptoms
requiring treatment for at least 7 days. Patients were excluded if
they had received a blood transfusion in the preceding 4 months,
had significant renal impairment, smoked or were on any med-
ications known to alter red cell cation transport, including
hydroxyurea. Following consent, clinical and laboratory data
were recorded, including basic hematologic parameters, admis-
sions to hospital and Emergency Room attendances with compli-
cations of sickle cell disease in 2011. Full blood counts were per-
formed using a Siemens Advia system within 4 h of venesection.
Retinopathy was screened for routinely every 12 – 24 months
after the age of 14 by an experienced ophthalmologist, and was
graded according to the Goldberg classification;14 younger chil-
dren were only referred for formal ophthalmological review if
they had relevant visual symptoms.
Measurement of K-Cl cotransport
Venous blood was taken into EDTA and analyzed within 24 h.
Red cells were washed in MOPS-buffered saline, and suspended at
a hematocrit of 30% in test saline. Oxygen tension was controlled
using Eschweiler tonometers and a Wosthoff gas-mixing pump.
Cell suspensions were equilibrated for 15 min at the required oxy-
gen tension, before being diluted 10-fold into test tubes for flux
measurement. Cl–-dependent K+ influx was measured using
radioactive tracer assays for KCC activity, according to previously
published methods.15 As the transport is known to be affected by
oxygen tension in a way that differs between red cells from nor-
mal individuals and those from patients with sickle cell disease,15
KCC activity was measured at two different oxygen tensions (100
and 0 mmHg).
Measurement of red cell sickling 
Red cells were washed and suspended in basic saline (NaCl 145
nM, MOPS 10 nM, glucose 5 nM, pH 7.4 adjusted with Tris base)
at a hematocrit of 2%. The red cells were incubated in a tonome-
ter in the absence of oxygen for 60 min and fixed by the addition
of 0.3% glutaraldehyde. Within 10 min, 300-400 cells were count-
ed under light microscopy using an improved Neubauer hemocy-
tometer and the percentage of sickled cells (sickle0 %) was calcu-
lated.
Statistical analysis
An independent statistician gave advice. Data were normally
distributed, as assessed by a Q-Q plot. Parametric tests were used
as appropriate, including independent sample T-tests, correlation,
and linear regression. Two-tailed P values were used, and values
<0.05 were considered statistically significant. Analyses were per-
formed using SPSS version 21 (IBM, Portsmouth, UK).
This study was funded by the MRC. The MRC had no direct
input into the design, execution or interpretation of this study, nor
the preparation of this manuscript.
Results
Basic parameters
One hundred and eleven patients with HbSC disease
consented to take part in the study. Their basic laboratory
values are given in Table 1. Forty-eight (43.1%) were aged
16 years or younger. A comparison of distributions
between male and female patients showed that male
patients had significantly higher hemoglobin concentra-
tions and white cell counts, with other parameters being
equivalent across the sexes. Forty-one patients with HbSS
were recruited, and are compared to the HbSC patients in
Table 2. Twenty-nine (70.1%) HbSS patients were aged 16
years or younger. There were highly significant differ-
ences between the two types of sickle cell disease for all
D.C. Rees et al.
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Table 1. Basic laboratory features of patients with HbSC in the study. 
Males Female
N. Mean SD N. Mean SD P
Age  (years) 50 21.0 18.0 61 24.3 16.1 0.300
Hemoglobin (g/dL) 49 12.1 1.7 61 11.1 1.0 0.000
Reticulocytes (%) 49 3.8 1.5 61 3.6 1.5 0.385
MCHC (g/dL) 49 34.6 1.2 61 34.8 1.1 0.464
White cell count (x109/L) 49 7.8 3.0 61 6.5 2.4 0.012
Bilirubin (mmol/L) 50 26.4 16.1 60 24.8 26.1 0.701
AST (IU/L) 50 36.7 18.4 60 29.9 19.1 0.061
LDH (IU/L) 50 290 75 60 265 67 0.075
Creatinine (mmol/L) 50 63 31 60 57 27 0.242
HbF (%) 49 2.8 2.8 57 2.4 2.3 0.481
KCC100 49 3.57 1.30 61 3.30 1.36 0.293
KCC0 49 0.73 0.60 61 0.83 0.71 0.416
The P value refers to a comparison of mean values between males and females using the T-test. MCHC: mean cellular hemoglobin concentration; AST: aspartate transaminase, LDH:
lactate dehydrogenase. KCC100: K-Cl cotransport activity at 100 mmHg oxygen; KCC0: K-Cl cotransport activity at 0 mmHg oxygen, both measured as K+ influx (mmol/L cells.h).
parameters, indicating that these are distinct disorders and
cannot be analyzed together.
Determinants of K-Cl cotransport activity
in HbSC disease
There was no significant difference in erythrocyte KCC
activity between male and female patients in either the
oxygenated or deoxygenated state (Table 1); male and
females were subsequently analyzed together. KCC activ-
ity was significantly greater in the oxygenated state
(KCC100) than in the deoxygenated state (KCC0), with
mean K+ influx of 3.42 mmol/L cells.h versus 0.79 mmol/L
cells.h (paired-samples T-test, P<0.000). 
KCC activity was correlated against age, hemoglobin,
reticulocyte percent, mean cellular hemoglobin concentra-
tion (MCHC), white blood cell (WBC) count, bilirubin,
aspartate transaminase, lactate dehydrogenase (LDH),
serum creatinine and hemoglobin F (HbF) levels (Table 3).
KCC100 and KCC0 correlated with each other significantly
(R=0.574, P=0.000). KCC100 correlated positively and sig-
nificantly with age, reticulocyte percent, WBC count,
bilirubin and creatinine; KCC0 correlated significantly and
positively with age, reticulocyte percent, and creatinine,
and negatively with LDH and HbF percent. Overall KCC
activity increased with increasing age, reticulocytosis, and
serum creatinine, and decreasing levels of LDH and HbF.
Linear regression was used to assess the most significant
independent determinants of KCC100 and KCC0. For KCC100
the linear regression model included age, reticulocyte per-
cent, WBC count, bilirubin and creatinine. This model
explained 36% of the variability in KCC100 (R=0.60), and
only age (Beta=0.249, P=0.024) and reticulocyte percent
(Beta=0.314, P<0.001) maintained statistical significance.
Similarly, the significant independent determinants of
KCC0 were assessed using linear regression against age,
reticulocyte percent, creatinine, LDH and HbF percent.
This model explained 42% of the variability in KCC0
(R=0.65). As for KCC100, only age (Beta=0.642, P<0.001)
and reticulocyte percent (Beta=0.189, P=0.033) were inde-
pendently significant.
Determinants of K-Cl cotransport activity in HbSS
The pattern of KCC activity differed significantly in the
HbSS population studied, with a much smaller decrease in
activity in the deoxygenated state compared to the oxy-
genated state (Table 2). KCC100 was significantly higher in
HbSC patients than in HbSS ones, whereas KCC0 was sig-
nificantly lower in HbSC patients. As for the HbSC popu-
lation, KCC100 and KCC0 in patients with HbSS were cor-
related against age and relevant laboratory parameters.
KCC100 correlated significantly only with age (R=0.705,
P=0.002), whereas KCC0 correlated significantly with age
(R=0.394, P=0.012) and HbF (R=-0.407, P=0.009).
Association between K-Cl cotransport activity 
and red cell sickling
The percentage of deoxygenated sickled cells correlated
positively and significantly with KCC0 and KCC100 (Table
3). Variation in KCC0 accounted for 8.3% and variation in
KCC100 explained 10% of the variation in sickle0%.
Association between K-Cl cotransport activity 
and hospital attendance in HbSC disease
The combined number of hospital admissions and
Emergency Room attendances over 1 year was used as a
surrogate marker of the frequency of acute pain. The num-
ber of these emergency attendances in 2011 varied from
zero to five per patient, with a median of one and a mean
of 0.95; 55 (49.5%) patients had no hospital attendances.
Emergency hospital attendance was, therefore, analyzed
as a binary variable with the two categories of ‘no atten-
dances’ and ‘at least one attendance’. At least one atten-
dance was associated with significantly increased activity
of both KCC100 (mean 3.87 versus 3.20, P=0.009, independ-
ent samples T-test) and KCC0 (mean 0.96 versus 0.68,
P=0.037) (Figure 1) compared to KCC activity in those
patients with no admissions. There was no significant
effect of age on the likelihood of attendance, which might
have explained the link to KCC activity (mean age of
patients with no attendances 16.4 years versus age of
patients with at least one attendance 17.8 years; P=0.308).
Logistic regression analysis was used to ascertain the
effects of KCC100, age, hemoglobin, reticulocyte percent,
MCHC, WBC count, LDH, and HbF percent on the likeli-
hood that a patient would attend hospital as an emer-
gency in 2011. Only KCC100 was significantly associated
K-Cl cotransport activity in HbSC disease
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Table 2. Comparison of laboratory parameters of patients with HbSS and HbSC. 
HbSC HbSS
N. Mean SD N. Mean SD P
Age  (years) 110 22.8 17.0 41 14.0 9.2 0.002
Hemoglobin (g/dL) 110 11.5 1.4 41 8.5 1.3 <0.001
Reticulocytes (%) 110 3.7 1.5 41 11.8 5.3 <0.001
MCHC (g/dL) 110 34.7 1.2 41 32.6 1.6 <0.001
White cell count (x109/L) 110 7.1 2.7 41 10.7 2.6 <0.001
Bilirubin (mmol/L) 110 25.5 22.0 41 62.3 43.3 <0.001
AST (IU/L) 109 33.0 19 41 51.3 14.0 <0.001
LDH (IU/L) 110 276 72 41 552 150 <0.001
Creatinine (mmol/L) 110 59.9 29.0 41 41.1 15.1 <0.001
HbF (%) 106 2.6 2.5 41 8.3 5.1 <0.001
KCC100 110 3.42 1.33 40 2.68 1.10 0.002
KCC0 110 0.79 0.66 40 1.93 1.34 <0.001
The P value refers to a comparison of mean values between patients with HbSC and patients with HbSS using the T-test. MCHC: mean cellular hemoglobin concentration, AST:
aspartate transaminase, LDH: lactate dehydrogenase. KCC100: K-Cl cotransport activity at 100 mmHg oxygen, KCC0: K-Cl cotransport activity at 0 mmHg oxygen, both measured as
K+ influx (mmol/L cells.h).
with attendance (P=0.012), with increased activity associ-
ated with increased likelihood of attendance [Exp(B)
=1.78, 95% CI 1.14 – 2.79].
Similarly, a logistic regression was used to analyze the
effects of KCC0, age and laboratory parameters on the
likelihood of emergency attendance at hospital. No factors
were significant in this model, although KCC0 approached
significance [P=0.052, Exp(B) 2.40, 95% CI 0.99 – 5.77].
Association between K-Cl cotransport activity 
and hospital attendance in HbSS
Unlike in HbSC, there was no association between
emergency hospital attendance and KCC activity in HbSS
patients. Twenty-one patients did not attend hospital
urgently in 2011: these patients had a mean KCC100 activi-
ty of 2.50 and mean KCC0 activity of 1.71. These activities
did not differ significantly from measurements in the 18
patients who attended the Emergency Room on one or
more occasion, in whom the mean KCC100 was 2.90
(P=0.280) and mean KCC0 was 2.23 (P=0.240).
Association between K-Cl cotransport activity 
and retinopathy in HbSC disease
Eighty-six (77.5%) patients with HbSC disease were
assessed for retinopathy. Sixty-five had no retinopathy,
three had grade 1, two had grade 2, six had grade 3, nine
had grade 4, and one had grade 5. Because of the small
numbers, retinopathy was analyzed as a categorical vari-
able comparing those without retinopathy (76%) against
those with retinopathy (24%). The presence of retinopa-
thy was associated with significantly increased activity of
both KCC100 (mean 4.22 versus 3.15, P=0.002, independent
samples T-test) and KCC0 (mean 1.18 versus 0.66,
P=0.002). However, retinopathy was strongly associated
with increasing age with the mean age of patients without
retinopathy being 18.9 years compared to 35 years for the
patients with this ocular complication (P<0.001); this is
likely to be the explanation for the association between
KCC and retinopathy.
Logistic regression analysis was used to ascertain the
effects of KCC100, age, hemoglobin, reticulocyte percent,
MCHC, WBC count, LDH, and HbF percent on the likeli-
hood that a patient would have retinopathy. None of
these factors was statistically significant in explaining the
likelihood of retinopathy in this model. Similarly there
were no significant effects on retinopathy noted when
KCC0 was substituted into the regression.
Only a small number of patients with HbSS had signifi-
cant retinopathy in this study, making statistical analysis
inappropriate.
Discussion
KCC,  first identified in erythrocytes,16 refers to the elec-
troneutral-coupled transport of K+ and Cl- across mem-
branes and is believed to be important in the regulation of
cell volume.17 Cell swelling, mild acidity, magnesium deple-
D.C. Rees et al.
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Figure 1. Error bar plots, showing mean and 95% confidence inter-
vals, comparing KCC activity (mmol/L cells.h) in patients with no
emergency hospital attendances and those who attended more















Emergency hospital attendances in 2011
Emergency hospital attendances in 2011
KC
C 0
Table 3. Pearson correlation of age, laboratory parameters and sickling
against KCC100 and KCC0 in HbSC patients.
KCC100 KCC0
N. R P R P
Age (years) 110 0.339** 0.000 0.614** 0.000
Hemoglobin (g/dL) 109 0.116 0.084 0.039 0.687
Reticulocyte (%) 109 0.540** 0.000 0.280** 0.003
MCHC (g/dL) 109 -0.072 0.458 -0.131 0.174
White cell count 109 0.214* 0.026 0.144 0.136
(x109/L)
Bilirubin 109 0.235* 0.014 -0.019 0.843
AST (IU/L) 108 0.091 0.349 -0.043 0.655
LDH (IU/L) 109 -0.054 0.580 -0.219* 0.022
Creatinine 109 0.239* 0.012 0.372** 0.000
HbF (%) 105 -0.122 0.215 -0.244* 0.012
Sickle0 (%) 109 0.317** 0.001 0.289** 0.002
** correlation is significant at the 0.01 level (2-tailed), * correlation is significant at the
0.05 level (2-tailed). MCHC: mean cellular hemoglobin concentration, AST: aspartate
transaminase, LDH: lactate dehydrogenase. KCC100: K-Cl cotransport activity at 100
mmHg oxygen, KCC0: K-Cl cotransport activity at 0 mmHg oxygen, both measured as K+
influx (mmol/L cells.h).
tion, protein kinase inhibitors and oxidative stress
increase KCC activity; conversely, KCC activity is
reduced by cell shrinkage, marked acidity, alkalinization
and most bivalent cations. The gene responsible for this
activity (SLC12A4) was cloned in 1996 and codes for the
protein KCC1, which is similar to other cation-chloride
cotransporters.18 Subsequently RNA transcripts from
KCC3 (SLC12A6) and KCC4 (SLC12A7) were identified
in erythrocytes, together with two splicing variants,
although the exact role of these different entities is not
clear.19
In normal erythrocytes, KCC activity is high in reticu-
locytes but largely absent in mature cells. In HbSS cells,
activity is increased and this is thought to be one of the
important mechanisms causing red cell dehydration and
promoting HbS polymerization.20 However, KCC is par-
ticularly implicated in the unique pathophysiology of
HbSC disease, with KCC100 activity being two to three
times greater in HbSC cells compared to HbSS, although
prior to this study, this interpretation was reliant on
extrapolation of findings from only a small number of
patients.9,10,21
In our study of 110 patients with HbSC disease, KCC
activity varied widely between patients; KCC100 varied
from 0.44 to 7.61 mmol/L cells.h, and KCC0 varied from 0
to 3.02 mmol/L cells.h. Genetic differences may account
for some of this variability, but on linear regression, two
factors were independently associated with activity of
both KCC100 and KCC0: age and reticulocyte percent. The
correlation of KCC with reticulocyte percent is expected
based on the known increased KCC activity in younger
red cells, and this explained 7.8% of the variability in
KCC0 and 29% of the variability in KCC100.
However, the statistically significant increase of KCC
activity with age is novel: age accounted for 38% of the
variability of KCC0 and 11% of the variability of KCC100.
Some of this increase with age may be related to falling
HbF levels, or increasing creatinine, although neither of
these was significant on multiple regression. This increase
in KCC activity with age may contribute to the higher
incidence of complications in older patients, including
retinopathy22 and renal impairment,23 or may be a conse-
quence of altered renal function.
It is also apparent from our study that oxygen affects
KCC activity differently in red cells from patients with
HbSS and HbSC disease. In oxygenated HbSC red cells,
KCC activity is high, similar or greater than that in HbSS
red cells; but at decreasing oxygen tensions, KCC activity
is progressively inhibited, as in red cells from normal indi-
viduals. The reasons for these differences are not known,
but the altered behavior of HbC compared to HbA or HbS
is an obvious possibility. The concentration of soluble
oxyHb and the presence of deoxyHb to interact with reg-
ulatory sites at the membrane have been proposed as key
regulators of KCC activity.24 In this context, the presence
of crystals of HbC25 at high oxygen tension and their dis-
solution at low oxygen tension may be important. The
role of oxygen is clearly complicated in HbSC, and likely
to differ depending on many dynamic factors, including
pH, temperature and age of the red cell, but this study
raises the possibility that oxygen supplementation may
be harmful to patients with HbSC disease in some cir-
cumstances. Oxygen has no such potentially harmful
effects in HbSS.
The most striking finding of our study is that patients
with high KCC activity were more likely to present to
hospital with acute vaso-occlusive problems. Red cell
dehydration occurs at the beginning of the cascade of
pathological events which ends in hospital attendance,
and it is perhaps surprising that KCC shows such a clear
relationship to acute complications. Most biomarkers
identified in sickle cell disease measure epiphenomena
occurring as a consequence of vaso-occlusion,26 and few
reflect fundamental aspects of pathophysiology, such as
red cell dehydration. The specific importance of KCC in
HbSC disease is emphasized by the fact that the same
relationship is not seen in HbSS patients. This effect is
independent of age, and also cannot be assessed by meas-
uring MCHC, which was not related to KCC activity in
our study. Emergency hospital attendance is a difficult
endpoint, with a lot of ‘noise’ unrelated to the pathophys-
iology of sickle cell disease. However, it is a highly rele-
vant clinical endpoint and, although it may generate false
negative results, it is much less likely to cause a false pos-
itive result. We, therefore, think the result in this study is
likely to be real and important.
The presence of retinopathy was also strongly associat-
ed with increased KCC activity, although this association
is confounded by the effects of age. Logistic regression
suggests that age is responsible for both the increased
prevalence of retinopathy and increased KCC activity,
although further studies are needed to unpick this compli-
cated association.
KCC measurements are potentially useful as prognostic
biomarkers in HbSC disease, to identify those patients
more likely to follow a severe course and benefit from
more aggressive treatment. The assay used in this study
requires specialist laboratory skills and equipment,
although it may be possible to simplify the assay, as has
been done for the similarly complicated assay which
measures Psickle activity.27
This study also suggests that effective inhibition of
KCC could reduce acute complications in HbSC disease.
This approach was addressed in a randomized controlled
trial involving hydroxyurea and magnesium pidolate,
which was stopped early because of poor recruitment.
Magnesium, used to inhibit KCC activity, showed no
clinical benefit, although there was no measurable inhibi-
tion of KCC activity, reflecting that magnesium is a rela-
tively weak inhibitor.28
Our study suggests that KCC is a clinically relevant
measurement in HbSC; further investigations, including
longitudinal studies, assessment of activity in different
reticulocyte fractions and genetic studies to characterize
inherited variation in activity, are required.
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